289711-21-3 Usage
Description
D,L-SULFORAPHANE GLUTATHIONE is a white solid that is the major metabolite of Sulforaphane and is also known as the Glutathione adduct of Sulforaphane. It is a significant compound derived from the breakdown of glucosinolates in cruciferous vegetables, which has been extensively studied for its potential health benefits and therapeutic applications.
Uses
Used in Pharmaceutical Industry:
D,L-SULFORAPHANE GLUTATHIONE is used as a pharmaceutical agent for its potential therapeutic effects. It has been found to possess antioxidant, anti-inflammatory, and anti-cancer properties, making it a promising candidate for the development of new drugs targeting various diseases.
Used in Anticancer Applications:
In the field of oncology, D,L-SULFORAPHANE GLUTATHIONE is used as an anticancer agent. It has been shown to modulate several oncological signaling pathways, leading to the inhibition of tumor growth and progression. Additionally, it has demonstrated synergistic anticancer effects when combined with conventional chemotherapeutic drugs, enhancing chemo-sensitivity and efficacy in resistant cases.
Used in Nutraceutical Industry:
D,L-SULFORAPHANE GLUTATHIONE is also used in the nutraceutical industry as a dietary supplement. It is believed to provide health benefits, such as boosting the immune system, promoting detoxification, and supporting overall health.
Used in Research and Development:
In the research and development sector, D,L-SULFORAPHANE GLUTATHIONE is used as a key compound for studying the mechanisms of action and potential applications of Sulforaphane and its derivatives. This helps in the development of new drugs and therapies for various diseases, including cancer.
Used in Drug Delivery Systems:
To enhance the bioavailability and therapeutic outcomes of D,L-SULFORAPHANE GLUTATHIONE, novel drug delivery systems have been developed. These systems employ various organic and metallic nanoparticles as carriers for the compound, aiming to improve its delivery and efficacy against target cells and tissues.
Check Digit Verification of cas no
The CAS Registry Mumber 289711-21-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,9,7,1 and 1 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 289711-21:
(8*2)+(7*8)+(6*9)+(5*7)+(4*1)+(3*1)+(2*2)+(1*1)=173
173 % 10 = 3
So 289711-21-3 is a valid CAS Registry Number.
InChI:InChI=1/C16H28N4O7S3/c1-30(27)7-3-2-6-18-16(28)29-9-11(14(24)19-8-13(22)23)20-12(21)5-4-10(17)15(25)26/h10-11H,2-9,17H2,1H3,(H,18,28)(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t10-,11-,30?/m0/s1
289711-21-3Relevant articles and documents
Glucoraphanin and sulforaphane evolution during juice preparation from broccoli sprouts
Bello, Cristiano,Maldini, Mariateresa,Baima, Simona,Scaccini, Cristina,Natella, Fausta
, p. 249 - 256 (2018)
Broccoli sprouts are considered functional food as they are naturally enriched in glucoraphanin (GR) that is the biological precursor of the anticancer compound sulforaphane (SFN). Due to its health promoting value, also broccoli sprout juice is becoming
A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity
Tran, Kim T.,Pallesen, Jakob S.,Solbak, Sara M.,Narayanan, Dilip,Baig, Amina,Zang, Jie,Aguayo-Orozco, Alejandro,Carmona, Rosa M. C.,Garcia, Anthony D.,Bach, Anders
supporting information, p. 8028 - 8052 (2019/10/11)
Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood-brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance - and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.
